Abstract
The development and progression of melanoma tumors is associated with angiogenesis, manifesting as changes in vessel density, morphology, and architecture that may extend through the entire skin depth. Three-dimensional imaging of vascular characteristics in skin lesions could allow diagnostic insights not available to the conventional visual inspection. Raster-scan optoacoustic mesoscopy (RSOM) has emerged as a unique modality to image microvasculature through the entire skin depth with resolutions of tens of micrometers, offering new possibilities to assess angiogenetic processes. However, current RSOM implementations are slow, exacerbating motion artifacts and reducing image quality, particularly when imaging melanoma lesions that often appear on the upper torso where breathing motion is strongest. To visualize for the first time melanoma vasculature in humans, in high-resolution, we accelerated RSOM scanning using an illumination scheme that is co-axial with a high-sensitivity ultrasound detector path, yielding 15 second single-breath-hold scans that minimize motion artifacts. Applied to 10 melanomas and 10 benign nevi in humans, we demonstrate visualization of microvasculature with performance never before shown in vivo. We show marked differences between malignant and benign lesions, supporting the possibility to use vasculature as a biomarker for lesion characterization. The study points to promising clinical potential for Fast-RSOM (FRSOM) as a three dimensional visualization method that can enable the complete assessment of microvascular parameters of melanoma and improve diagnostics.
Competing Interest Statement
Vasilis Ntziachristos is an equity owner in and consultant for iThera Medical GmbH, Munich, Germany.
Funding Statement
This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 687866 (INNODERM) and under grant agreement No 871763 (WINTHER).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Twenty lesions (10 melanomas from 10 patients and 10 nevi from 9 patients) were imaged following approval from the Ethics Committee of Klinikum Rechts der Isar der Technischen Universitaet Muenchen, Munich, Germany.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.